Latest Conference Articles

ASH 2025 highlights groundbreaking advancements in multiple myeloma treatment, focusing on bispecific T-cell antibodies for improved patient outcomes.

Matthew Matasar, MD, discusses real-world data on treatment options for diffuse large B-cell lymphoma.

Imlunestrant shows significant progression-free survival benefits in advanced breast cancer, offering a promising treatment option for patients.

Giredestrant combined with everolimus significantly improves progression-free survival in advanced ER+, HER2-negative breast cancer after CDK4/6 inhibitors.

GC012F/AZD0120 CAR T-cell therapy shows 100% response rate in newly diagnosed multiple myeloma, offering hope for diverse patient groups.

Gedatolisib combined with fulvestrant shows significant progression-free survival benefits in advanced breast cancer, regardless of prior treatment duration.

Remote monitoring enhances infection management in hematologic malignancies, reducing hospitalizations and improving patient communication for better outcomes.

Long-term PALLAS study results reveal no survival advantage for palbociclib plus endocrine therapy over endocrine therapy alone in breast cancer patients.

New research reveals hormone replacement therapy may lower breast cancer risk in BRCA carriers, challenging existing medical guidelines on HRT use.

Elacestrant shows promising results in combination therapies for ER-positive, HER2-negative metastatic breast cancer, enhancing progression-free survival and maintaining safety.

A safety analysis reveals that sacituzumab govitecan and pembrolizumab combination therapy shows manageable side effects in treating metastatic triple-negative breast cancer.

A novel ctDNA assay identifies high-risk triple-negative breast cancer patients post-surgery, highlighting its potential as a crucial prognostic tool.

Alpelisib plus fulvestrant significantly improves progression-free survival in advanced breast cancer patients previously treated with CDK4/6 inhibitors.

Circulating tumor DNA analysis offers a minimally invasive method for detecting key genetic alterations in hormone receptor-positive breast cancer patients.

Dr. Robert Orlowski highlights strategies to prevent infections in multiple myeloma patients treated with linvoseltamab, emphasizing antiviral prophylaxis and IVIG use.

New research shows less invasive surgical options for breast cancer staging are as effective as traditional methods, enhancing patient quality of life.

New research reveals that preoperative breast MRI does not enhance outcomes for early-stage breast cancer patients, challenging its routine use in treatment plans.

New trial data reveals that combining preoperative radiation with pembrolizumab enhances immune response in high-risk, early-stage breast cancer patients.

Abemaciclib shows promise as a monotherapy for HR-positive, HER2-negative breast cancer after CDK4/6 inhibitor failure, benefiting 33% of patients.

Sacituzumab govitecan enhances quality of life for untreated advanced TNBC patients, despite increased gastrointestinal toxicities compared to chemotherapy.

The FDA reviews nivolumab with chemotherapy as a potential new frontline treatment for advanced classical Hodgkin lymphoma, promising improved outcomes.

Subgroup analyses reveal T-DXd significantly improves invasive disease-free survival in early-stage HER2-positive breast cancer compared to T-DM1, regardless of HER2 expression.

A recent study reveals critical insights on disease progression and survival rates in patients with relapsed/refractory large B-cell lymphoma treated with bispecific antibodies.

Tucatinib enhances frontline maintenance therapy for HER2-positive metastatic breast cancer, significantly improving progression-free survival compared to placebo.

An innovative AI model enhances breast cancer recurrence predictions, outperforming traditional methods and offering tailored treatment insights for patients.

Patients in the DESTINY-Breast09 trial report improved quality of life with T-DXd plus pertuzumab, highlighting distinct side effect profiles compared to standard care.

New data reveals that the BPd treatment combination significantly improves outcomes in relapsed multiple myeloma, outperforming traditional therapies.

A phase 2 study reveals promising efficacy and safety of TKI and inotuzumab ozogamicin therapy for newly diagnosed Ph+ ALL, achieving high response rates.

Giredestrant shows significant improvement in invasive disease-free survival for early breast cancer patients, outperforming standard endocrine therapy in a pivotal trial.